Evoq Remedies Ltd.
EVOQ.BO
Bombay Stock Exchange2.42
INR
+0.06
- -
Evoq Remedies Ltd.
EVOQ.BO
(Bombay Stock Exchange)
Recent
price
2.42
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Evoq Remedies Limited engages in the pharmaceutical business in India, primarily through marketing, trading, distribution, and acting as a commission agent for a wide range of pharmaceutical formulation products, active pharmaceutical ingredients, nutraceuticals, ayurvedic, and herbal products. The company offers approximately 120 products under its own brand name, including antibiotic drugs, anti-malarial drugs, anti-allergic and anti-cold drugs, analgesic/antipyretic and anti-inflammatory drugs, dermatology products, cerebral activator drugs, neurological drugs, gastrointestinal drugs, steroids, gynecology drugs, calcium supplements, multivitamins, anti-oxidants, and injections; it also trades in sweeteners such as acesulfame potassium, aspartame, and dextrose, amino acids including L-alanine and L-arginine, excipients like bronopol and HPMC, ointments containing adapalene, clobetasol propionate, and clotrimazole, vitamins, sterile products, dairy and spice products, and veterinary feed products, with manufacturing outsourced to third parties. Incorporated in 2010 as Salus Life Science and Research Private Limited, renamed Evoq Remedies Private Limited in 2019, and converted to a public company in 2021, the company is headquartered at A-1106, Empire Business Hub, Science City Road, Ahmedabad, Gujarat, India, and operates primarily in the domestic market. Recent developments include securing a substantial purchase order worth Rs 136 crore from Marlex Pharmaceuticals Inc., receiving INR 192.1 million in funding via private placement in June 2024, approving a public issue of 36 lakh equity shares raising Rs 9.72 crore in March 2022, and appointing Bhumishth Narendrabhai Patel as Managing Director in August 2024, alongside board discussions on preferential share issues and capital increases for growth.